All News

The leaders of the United Nations and the World Health Organization expressed renewed alarm on Friday about Ebola's tenacity in Africa and, in particular, its potential to ravage a fourth country, Mali, where they said hundreds of people had been exposed to an infected cleric who died last month.

Researchers at Vanderbilt University Medical Center have used electronic health record analysis to uncover hidden drug benefits, according to a study appearing in the Journal of the American Medical Informatics Association.

A HIPAA-compliant app developed by doctors at the Arnold Palmer Hospital for Children in Orlando, helps quell the anxiety of family members as their children undergo surgery.

Champions Oncology will be presenting data on it's preclinical model at the ongoing EORTC-NCI-AACR Symposium in Barcelona. The model proposes to help develop individualized treatments for patients.

In March, the Obama administration released guidance extending the renewal of health insurance policies that do not meet the Affordable Care Act's coverage standards through October 1, 2016. At least 9 states that did not adopt the administration's original transitional policy are now allowing renewals of noncompliant policies after January 1, 2014.

Randomized trials are highly effective for suggesting ways to improve healthcare delivery, but they're also rare. That may be changing.

Republicans finally filed a lawsuit against President Obama's healthcare reform law, the Affordable Care Act, after approving the suit in July. They are challenging the employer-based coverage aspect of the law, as well as Treasury payments to insurers.

Scientists at the Memorial Sloan Kettering Cancer Center have identified that tumor mutation burden could help predict responders to ipilimumab treatment. The report has been published online in the New England Journal of Medicine.

A recent study published in European Urology highlights quality-of-life benefits with active surveillance in men with prostate cancer.

Vermont Senator Bernie Sanders has introduced a bill that would require generic drugmakers to pay rebates to the federal Medicare and Medicaid programs when prices of their medications outpace inflation.

The study, published in Cell Reports, evaluates the dynamic protein interactions that promote different diseases including cancer. By capturing these interactions, the authors hope to discover new drug targets.

A new study shows only a small share of patients with private insurance who were newly diagnosed with diabetes in 2011-2012 enrolled in self-management training, raising questions about how well managed care could address both long-term health and cost control for this important group. These patients are a target for special attention under the ACA.

Being promised a 100% reimbursement, Gilead will now make the drug available to HCV patients in France at 60% of the cost in the United States.

The retrospective study, published in JAMA Surgery, could not necessarily point to the underlying reason for this treatment choice.

According to the report, sofosbuvir for hepatitis C infections and new cancer drugs were the drivers of the high spending costs, a 7% jump over the previous year.

Clinicians are showing increased openness toward using digital technology and are becoming more comfortable with trusting tools like at-home test results, according to a new report from PwC's Health Research Institute.

An examination of nearly 200 medication adherence trials found that it is actually difficult to determine whether or not the approaches truly worked.

Employee wellness programs are now being supported by apps developed by technology giants like Google and Apple. But are they really helping keep patients engaged and on-track with their health goals?

With an aim to create parity between brand-name and generic drugs, the FDA was expected to pass a rule next month that would allow generic manufacturers to independently provide safety updates on their labels. The decision has now been pushed back by 9 months.

In an effort to foster greater transparency of healthcare costs, the government and private sector entities are offering tools that provide cost and quality information to consumers. But just how effective are these tools?

Results presented today at the American College of Rheumatology in Boston show that a 12-biomarker test did a better job of predicting radiographic progression in patients with RA. The study demonstrates how biomarkers are becoming important in managed care outside of cancer treatment.

After 4 years of living with inflammatory breast cancer, Amy Berman, RN, BS, senior program officer at the John A. Hartford Foundation, she still felt fine, which she attributed to her care choices, she explained during her speech at The American Journal of Managed Care's Patient-Centered Oncology Care meeting in Baltimore, Maryland.

The study, published in the Journal of Thoracic Oncology, identified race, insurance status, and the treatment center as variables that influenced treatment received by individuals with early-stage lung cancer.

In a paper published in the Journal of Clinical Oncology, medical oncologists have delineated their recommendations to improve cancer care and provide better access to quality care for those patients with financial issues and on Medicaid.

One-fifth of adults with health insurance spent at least 5% of their income on out-of-pocket healthcare costs over the past year with low-income adults the most likely to have high costs, according to a report from The Commonwealth Fund.

ZMapp, which has been developed by Mapp Biopharmaceutical, was successful in 5 of 7 Ebola-infected patients; but the mechanism of it's action in those patients was not very clear.

The study, published in Environmental Health Perspectives, studied the BMI of children in Southern California over a period of 8 years, and studied it's correlation with environmental pollutants.

Thursday is the Great American Smokeout, an event founded on this date in California in 1976. This year, the event comes amid the 50th anniversary celebration of the report to the US Surgeon General that started public health efforts to curb tobacco use.

Patients taking Merck's Vytorin, which combines simvastatin with the non-statin Zetia, experienced fewer major cardiovascular events than patients treated with simvastatin alone, according to the results of the IMPROVE-IT study.

An electrical device glued to the scalp can slow cancer growth and prolong survival in people with the deadliest type of brain tumor, researchers reported on Saturday in Miami, at a meeting of the Society for Neuro-Oncology.